2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

5015 A CSF inhibitory assay demonstrates potent FLT3 inhibition by gilteritinib in the cns

Kiarash Salafian, MD, Teodora Diana Supeanu, DVM, PhD2, Gabriel Ghiaur, MD, PhD3, Mark J. Levis I, MD PhD4
1 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
2 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
3 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
4 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Introduction: Central nervous system (CNS) involvement by acute myeloid leukemia (AML) is a form of extramedullary involvement generally associated with a poor prognosis.  Clinical and molecular features of AML predicting for CNS involvement include high white blood cell (WBC) count at diagnosis, extramedullary disease such as leukemia cutis or myeloid sarcoma, and the presence of a FLT3-ITD mutation (Jabbour et al. Am J Hematol. 2017).  Gilteritinib is a small molecule FLT3 inhibitor approved for the treatment of relapsed and/or refractory FLT3-mutated AML.  There are several case reports of gilteritinib having clinical activity in patients with CNS involvement, despite the concentration of gilteritinib in cerebrospinal fluid (CSF) being < 5% of that in plasma (Vignal et al. Haematologica 2023).  Dosing for gilteritinib was in part determined using a well-validated surrogate assay for in vivo FLT3 inhibitory activity known as the plasma inhibitory activity assay for FLT3 (FLT3 PIA assay; Levis et al. Blood 2006).  We applied a variation on this assay to CSF samples collected from patients taking gilteritinib in order to establish the degree of FLT3 inhibition induced in CSF by this drug compared to that observed in plasma.

Methods: CSF and whole blood samples were collected from patients during lumbar punctures and phlebotomy performed as part of standard clinical care.  Samples were collected under an IRB-approved protocol.  All patients gave informed consent.  CSF collected from patients not on any FLT3 inhibitor was pooled and gilteritinib was spiked in for standard curve generation.  Molm14 cells were incubated in CSF, cell culture medium, or plasma either with gilteritinib spiked in or with CSF and plasma collected from patients on gilteritinib.  All patients on gilteritinib were on the drug continuously for at least 4 weeks prior to sample collection.  Western blotting for phosphorylated FLT3 (P-FLT3) was performed as described (Levis et al. Blood 2006).  FLT3 ligand (FL) concentration was determined by ELISA.

Results: In dose-response experiments, gilteritinib potently inhibited FLT3/ITD autophosphorylation in CSF with a half-maximal inhibitory concentration (IC50) of 2 nM, approximately 20-fold lower than in plasma (~40 nM) and comparable to culture medium (~3 nM).  To evaluate the CSF FLT3 inhibitory activity (FLT3 CIA) of gilteritinib, a total of 8 paired plasma and CSF samples from 6 different patients actively taking gilteritinib were collected.  Of these patients, 4 had CNS involvement at some point during their disease course.  At the time of sample collection, all patients were receiving gilteritinib 120 mg/day, with the exception of one patient receiving 80 mg/day.  The CIA assay demonstrated highly effective FLT3 target inhibition in CSF, with inhibitory activity comparable to that in plasma.  In plasma, the range of inhibition was 61.5% - 86.9% (median 83%), and in CSF, the range was 67.2% - 84.3% (median 79.1%).  Mass spectroscopic analysis of drug concentrations is in process.  Overall signal intensity of P-FLT3 was reduced in CSF compared to plasma, suggesting a difference in the cytokine milieu between the two compartments.  We therefore evaluated the presence and potential impact of FL on the efficacy of FLT3 inhibition in both compartments.  Notably, ELISA testing revealed uniformly low levels of FL in CSF (17-68 pg/mL), but increased levels in the plasma (525-1380 pg/mL) of these patients, most of whom were undergoing active treatment.

Conclusions: Based on these data, gilteritinib effectively inhibits FLT3 in the CNS at conventional clinical doses.  Its potency in the CNS is likely due to the lower levels of drug-binding protein in CSF compared to plasma as well as to the distinctly lower concentrations of FL in CSF.  Our findings illustrate that small molecule inhibitors can potentially be effective in the CNS at much lower concentrations compared with plasma due to lower levels of drug-binding proteins in the CSF and perhaps also to a different cytokine environment.  We are currently evaluating the FLT3 inhibitory activity of other FLT3 inhibitors in the CNS for comparison.

Kiarash Salafian, MD: No relevant conflicts of interest to declare.